We have received approval from The Norwegian Food Safety Authority (Mattilsynet) to test our Alvacan 1000 and 4000 immune cell-based vaccines in 30 privately owned dogs with cancer. The approval means that the planned clinical trial is approved according to Animal Welfare legislation. The aim of the clinical trial is to garner data on the safety and efficacy of the vaccines, and our major goal is improving both the quality of life and life expectancy of privately owned dogs with malignant mammary tumours and soft tissue sarcomas, which are otherwise difficult to treat or often untreatable. The trial is led by our Head of Clinical Development, Dr. Prof. Lars Moe, in collaboration with our lead veterinary clinic the Department of Companion Animal Clinical Sciences at NMBU (Ås) and the partners clinics Frederikstad Dyreklinikken (Frederikstad) and AniCura Jeløy (Moss).
This represents one of the largest, if not the largest, study of its kind in. Our trial will mark the beginning of using autologous vaccines, i.e. a vaccine using the cells of the patients themselves, and a shift in the way we approach cancer in dogs in the future. We are paving the way to bring immunotherapy and cancer vaccines to the forefront of veterinary medicine here in Norway, and globally.
Enrolment of canine patients into the trial is pending final approval from the Norwegian Medicines Authority. We eagerly anticipate the commencement of the trial, and are excited to see our vaccines beginning to help those dog patients that need it the most.
